ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
ION Breast Cancer Clinical Pathways - ION Solutions
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Xeloda (Capecitabine) +/- Avastin (Bevacizumab) EP=Low; FN> J Clin Onc19:4097-4106,2001<strong>Clinical</strong> Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Colon: Second Line MetastaticChemotherapy:mFOLFOX 6 +/- Avastin (Bevacizumab) EP=Moderate; FN=10%-20%Oxaliplatin 85mg/m 2 D1, D15Leucovorin 400mg/m 2 D1, D155-Fluorouracil 400mg/m 2 IVP D1, D155-Fluorouracil 2400mg/m 2 CI over 46 hours D1, D15+/- Bevacizumab 5mg/kg D1, D15q 28 Day Cycle>> J Clin Oncol 26:2006-2012, 2008>> Br J <strong>Cancer</strong> 87:393-399, 2002>> BMC <strong>Cancer</strong> 7:91, 2007CapeOx +/- Avastin (Bevacizumab) EP=Moderate; FN> J Clin Oncol 26:2006-2012, 2008>> J Clin Oncol 26:2013-2019, 2008FOLFIRI +/- Avastin (Bevacizumab) EP=Moderate; FN=10%-20%Irinotecan 180mg/m 2 D1, D15Leucovorin 400mg/m 2 D1, D155-Fluorouracil 400mg/m 2 IVP D1, D155-Fluorouracil+/- Bevacizumab 5mg/kg D1, D15q 28 Day Cycle>> Eur J <strong>Cancer</strong> 35:1343-1347, 1999>> J Clin Oncol 25:4779-4786, 20072400mg/m 2 CI over 46 hours D1, D15Page 17 of 39© 2013 by <strong>ION</strong> <strong>Solutions</strong>. All rights reserved
Change language